title: Adriamycin promotes neurite outgrowth in the "neurite-minus" N1A-103 mouse neuroblastoma cell line.
abstract: Adriamycin, an anticancer agent acting on topoisomerase II, promotes the arrest of cell division and neurite extension in a "neurite-minus" murine neuroblastoma cell line, N1A-103. This morphological differentiation is accompanied by a blockade in the S phase of the cell cycle, modification of the amount of peripherin, and appearance of the beta 7-tubulin isoform. Yet, adriamycin-induced N1A-103 cells fail to express other neuronal markers, such as long-lasting Ca2+ channels, synaptophysin, and the shift in the proportion of the beta'1 tubulin isoform to the beta'2 isoform, whose appearance parallels the terminal differentiation of the wild type neuroblastoma cell line N1E-115. Hence, a comparison of the behavior of these two cell lines leads to the proposal that there are two programs of neuroblastoma differentiation: one where expression is triggered by the arrest of cell division and which is observed in adriamycin-induced N1A-103 variant cells, and the other, presumably occurring further downstream, which would involve further changes in morphogenesis and acquisition of new electrophysiological properties.
authors.affiliation: Laboratoire de Biochimie Cellulaire, URA 1115, Collège de France, Paris.
authors.forename: J C
authors.initials: JC
authors.lastname: Larcher
authors.forename: L
authors.initials: L
authors.lastname: Cordeau-Lossouarn
authors.forename: G
authors.initials: G
authors.lastname: Romey
authors.forename: F
authors.initials: F
authors.lastname: Gros
authors.forename: B
authors.initials: B
authors.lastname: Croizat
authors.forename: J L
authors.initials: JL
authors.lastname: Vayssiere
mesh_terms: D000818:Animals; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology; D004273:DNA, Neoplasm / Q000096:biosynthesis / Q000302:isolation & purification; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology*; D007381:Intermediate Filament Proteins / Q000378:metabolism; D007700:Kinetics; D008562:Membrane Glycoproteins; D051379:Mice; D009419:Nerve Tissue Proteins; D016501:Neurites / Q000187:drug effects* / Q000648:ultrastructure; D009447:Neuroblastoma; D009479:Neuropeptides / Q000378:metabolism; D064531:Peripherins; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D015222:Sodium Channels / Q000187:drug effects / Q000502:physiology; D013936:Thymidine / Q000378:metabolism*; D014404:Tubulin / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D015220:Calcium Channels; D003509:Cyclohexanecarboxylic Acids; D004273:DNA, Neoplasm; D007381:Intermediate Filament Proteins; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D009479:Neuropeptides; D064531:Peripherins; D015222:Sodium Channels; D014404:Tubulin; C027655:1-methylcyclohexanecarboxylic acid; D004317:Doxorubicin; D010751:Phosphopyruvate Hydratase; D013936:Thymidine; D004121:Dimethyl Sulfoxide